This testosterone bone health claim needs context

What did @dr_douglucas actually say?

The short version: testosterone is anabolic, women need it too, and if your levels are low, you're missing one of the body's key tools for building muscle and bone. He was careful to say testosterone is "not an osteoporosis drug" and not a "standalone solution," but framed low testosterone as a physiological obstacle to bone-building strategies. He also argued that FDA approval guidelines are "the floor, not the ceiling" for evidence for off-label use in women.

That's a reasonable clinical framing, not a miracle-cure pitch. He didn't recommend doses, didn't claim testosterone reverses osteoporosis, and acknowledged the limits of current approved indications. That restraint matters, because this topic gets distorted quickly in both directions.

Does the science back this up?

Largely, yes, though with important caveats about causation and study design. The association between testosterone and bone mineral density in women is real and appears across multiple study types, but the evidence for supplementation specifically is thinner than the evidence for endogenous levels.

A 2019 meta-analysis by Islam et al. in The Journal of Clinical Endocrinology and Metabolism found that testosterone therapy in postmenopausal women was associated with modest improvements in bone mineral density, particularly at the lumbar spine. A large observational study by Laughlin et al. (2008, Osteoporosis International) found that higher endogenous testosterone in older women correlated with greater bone mineral density and lean mass. The anabolic mechanism is also reasonably well established: testosterone acts directly on androgen receptors in bone and muscle, and partially converts to estradiol via aromatase, which adds another bone-protective pathway.

His claim that women often have "as much, if not more testosterone than estradiol when you adjust for units" is accurate in a technical sense. Testosterone is measured in nanograms per deciliter and estradiol in picograms per milliliter, so the molar comparison does change the picture, though this framing can confuse more than it clarifies for a general audience.

What did they get wrong (or right)?

He got the core physiology right. Testosterone is anabolic, women produce it, and low levels are a plausible contributor to reduced muscle and bone maintenance. The point about guidelines being a floor and not a ceiling is defensible, though it deserves more nuance than it gets here.

Where this starts to slide is in the implicit clinical logic: that if testosterone levels are "low," supplementation will fill that gap and support bone. The jump from "higher endogenous testosterone correlates with better bone density" to "giving testosterone to low-testosterone women improves bone outcomes" is not fully supported by randomized controlled trial data. Correlation studies are not the same as intervention studies. The Islam et al. meta-analysis showed modest BMD benefits, but most included trials were short-term and used varying formulations and doses. The evidence base for testosterone as a bone-specific intervention in women is still developing.

He also glosses past the fact that the only FDA-approved indication for testosterone in women is hypoactive sexual desire disorder, not bone health or general hormone optimization. That's not a trivial distinction in a clinical setting.

What should you actually know?

If you're a woman over 40 concerned about bone loss, testosterone is one piece of a complicated picture, not a missing key. The primary evidence-based interventions for bone health remain resistance training, adequate calcium and vitamin D, and in some cases, estrogen therapy or medications like bisphosphonates for diagnosed osteoporosis.

Testosterone's role in women's bone health is biologically plausible and supported by some data, but it has not been studied long enough or at scale to be recommended as a bone-protective therapy on its own. If you have symptoms of low testosterone, including low libido, fatigue, or difficulty maintaining muscle mass, that's a conversation worth having with a provider who can run appropriate labs and assess your full hormonal picture. Off-label use is not inherently wrong, but it requires informed consent and clinical judgment, not a 60-second Instagram framing.

The takeaway from this video is reasonable: don't ignore testosterone when thinking about musculoskeletal health in women. But treat it as a starting point for a clinical conversation, not a conclusion.